Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993892 | 0.91 | HTR6 (0.49) | NPC1MAPK1TSHRMAPTALDH1A1 | |
| SCHEMBL1345394 | 0.79 | MAPKAPK2 (0.52) | NPC1MAPK1MAPKAPK2MAP2K1TRPV1 | |
| SCHEMBL12131763 | 0.79 | HTR6 (0.51) | NPC1MAPK1MAPTALDH1A1RAB9A | |
| SCHEMBL12131764 | 0.78 | HTR6 (0.53) | NPC1MAPK1MAPTALDH1A1RAB9A | |
| SCHEMBL3000961 | 0.74 | HTR6 (0.53) | NPC1MAPK1MAPTALDH1A1RAB9A | |
| SCHEMBL2990204 | 0.74 | NAMPT (0.52) | NPC1MAPK1TSHRMAPTALDH1A1 | |
| SCHEMBL1345624 | 0.74 | MAPT (0.47) | TSHRMAPTALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1343706 | 0.72 | MAPKAPK2 (0.44) | NPC1MAPK1MAPKAPK2MAP2K1 | |
| SCHEMBL1345952 | 0.70 | MAPT (0.50) | NPC1MAPTMAPKAPK2RAB9A | |
| SCHEMBL12131765 | 0.68 | NQO2 (0.53) | NPC1MAPK1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | NPC1 4214/4885MAPK1 33/4885TSHR 3572/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | NPC1 4214/4885MAPK1 33/4885TSHR 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.